Consensus statement on the multidisciplinary treatment of nasopharyngeal carcinoma with immune checkpoint inhibitors in China
ICIs are recommended for the treatment of nasopharyngeal carcinoma, particularly in high‑risk and recurrent/metastatic disease.
Given the differences in drug approval and availability across countries and the high incidence of NPC in southern China, this consensus particularly focuses on the treatment of Chinese patients.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Efficacy and Toxicity of Triweekly Versus Weekly Cisplatin in Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
- Anti‑PD‑1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double‑blind phase 3 study
- Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma
- Nasopharyngeal Cancer
- Hierarchical dynamic model for risk‑stratified screening of nasopharyngeal carcinoma